Abrostep NM Tablet contains Acebrophylline 100 mg, N-Acetylcysteine 600 mg, and Montelukast 10 mg, a triple-action formulation designed for effective respiratory care.
Acebrophylline works as a bronchodilator, relaxing bronchial smooth muscles and improving airflow. N-Acetylcysteine acts as a mucolytic, breaking down thick mucus to ease expectoration. Montelukast is a leukotriene receptor antagonist, helping in reducing airway inflammation and managing allergy-driven respiratory issues.
Clinically, Abrostep NM Tablet is indicated for chronic bronchitis, COPD, asthma, and other obstructive airway diseases, providing improved breathing, reduced inflammation, and enhanced patient comfort. Its tablet form ensures accurate dosing, stability, and patient compliance.
From a business perspective, Abrostep NM Tablet strengthens the respiratory therapy segment, widely used in clinics, hospitals, and pulmonary care centers, offering consistent demand, repeat prescriptions, and strong prescriber trust.